China Cracks Down on Foreign Brokers: Futu, Tiger & Longbridge Face Penalties
China is cracking down on brokers helping locals invest abroad, restricting accounts to stop illegal money outflows.
NOTRELOAD AI
Oklo Gets Bullish Wall Street Backing as BofA Initiates Buy Coverage
BofA highlights Oklo’s build-own-operate SMR model, its 1.2 GW deal with Meta, and a large customer pipeline.
Mizuho Turns Positive on Q32 Bio’s Bempikibart, Initiates Coverage with Outperform Rating
Mizuho sees Q32 Bio upside with $14 target vs ~$5.50, boosted by bempikibart alopecia drug progress and 2026 data.
Parkinson’s Drug Targeting LRRK2 Fails Key Phase 2 Trial, Biogen and Denali Halt Development
Experimental Parkinson’s drug BIIB122 failed to slow disease in trials despite strong biological effects; development stopped.
Wall Street Turns Cautious on Summit Therapeutics: Bernstein Slaps Underperform Rating, Predicts Phase 3 Failures
Analysts warn Summit may fail key trials, lacks revenue, and faces pressure—raising doubts about its future and stock upside.
Zoom Beats Q1 Expectations and Raises 2027 Outlook as AI Adoption Accelerates
Zoom beat forecasts, boosted earnings and revenue outlook, as AI tools drove strong user growth and investor confidence.